FMC Corporation Faces Revenue Decline and Strategic Options After Q4 Earnings Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 22 2026
0mins
Should l Buy FMC?
Source: Fool
- Significant Sales Decline: FMC Corporation reported an 18% drop in full-year revenue for 2025, with an 8% decline excluding the impact of exiting the Indian market, indicating a weakening competitive position that may further erode investor confidence.
- Worrisome Financial Condition: The company posted a loss of $17.88 per share against a current stock price of $14.48, highlighting severe financial strain, as FMC carries $3.5 billion more debt than cash, prompting management to seek $1 billion through asset sales and licensing agreements to reduce debt.
- Exploration of Strategic Options: FMC announced it would explore strategic options to maximize shareholder value, including a potential sale of the company, although there is no assurance that this process will lead to a successful transaction, reflecting the company's dual focus on revitalization and possible market exit.
- New Product Development Plans: The company plans to commercialize four new herbicides and fungicides to drive revenue growth, despite management forecasting a 5% revenue decline in 2026; successful product launches could provide new growth opportunities for FMC amidst ongoing challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FMC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FMC
Wall Street analysts forecast FMC stock price to rise
14 Analyst Rating
3 Buy
10 Hold
1 Sell
Hold
Current: 14.650
Low
13.00
Averages
19.08
High
28.00
Current: 14.650
Low
13.00
Averages
19.08
High
28.00
About FMC
FMC Corporation is a global agricultural sciences company engaged in providing farmers solutions that increase the productivity and resilience of their land. The Company’s crop protection solutions, including biologicals, crop nutrition, digital and precision agriculture, enable growers and crop advisers to address their challenges economically while protecting the environment. Its portfolio consists of three major pesticide categories: insecticides, herbicides and fungicides. The majority of its product lines consist of insecticides and herbicides, and it has a portfolio of fungicides mainly used in high-value crop segments. Its insecticides are used to control a wide spectrum of pests, while its herbicide portfolio primarily targets a large variety of difficult-to-control weeds. In addition, it is also investing in its Plant Health program, which includes biologicals, crop nutrition, and seed treatment products. Biological technologies serve as complements to its synthetic products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FMC Corporation Q1 2026 Earnings Call Insights
- Sales Performance Overview: FMC reported Q1 sales of $762 million, a 4% decline year-over-year, yet a 1% increase on a like-for-like basis after excluding India, demonstrating resilience amid challenging market conditions.
- Debt Management Plan: The company aims to reduce approximately $1 billion in debt during 2026 and expects to sign a definitive agreement for the sale of its India commercial business in May, which will help improve financial health and reduce leverage.
- Product Strategy Shift: FMC is transitioning production from high-cost plants to lower-cost sources in Asia, with completion expected by Q1 2027, thereby enhancing overall production efficiency and reducing costs.
- Future Outlook: The company anticipates Q2 revenue between $850 million and $900 million, with adjusted earnings per share expected to range from $0.16 to $0.26, maintaining full-year guidance despite uncertainties related to Iran and tariffs.
See More
FMC STOCK RISES 11.4% FOLLOWING STRONG Q1 REVENUE AND SMALLER-THAN-EXPECTED LOSS
Revenue Performance: The company reported a revenue increase of 1.4% after exceeding expectations in Q1.
Losses: Despite the revenue beat, the losses were narrower than anticipated.
See More
FMC (FMC) Q1 2026 Earnings Call Transcript
See More
FMC Reports Q1 2026 Earnings with Mixed Results
- Earnings Beat: FMC's Q1 non-GAAP EPS of $0.23 exceeded expectations by $0.61, indicating resilience in profitability despite a 4.1% year-over-year revenue decline.
- Revenue and Loss: The company reported revenue of $759 million, beating estimates by $16.59 million, yet faced a GAAP net loss of $281 million, a decline of $266 million compared to Q1 2025, highlighting ongoing challenges.
- Adjusted EBITDA Decline: Adjusted EBITDA fell to $72 million, down 40% year-over-year, suggesting a need for improved cost control and operational efficiency to navigate market pressures.
- 2026 Outlook Maintained: FMC maintains its full-year 2026 outlook with projected revenue between $3.60 billion and $3.80 billion, reflecting a cautious stance as it anticipates a 5% decline at the midpoint compared to 2025.
See More
FMC Corporation Reports Q1 2026 Financial Results and Strategic Outlook
- Revenue Decline: FMC Corporation reported Q1 2026 revenue of $759 million, a 4% decrease year-over-year, with revenue excluding India at $762 million, indicating significant challenges in the global market, particularly due to a 5% sales headwind from the divestiture of its India business.
- Widening Loss Per Share: The company reported a diluted loss per share of $2.25 for Q1, an increase of $2.13 compared to the same period in 2025, reflecting pressures from restructuring costs and higher interest expenses that have worsened its overall financial condition.
- Significant EBITDA Drop: Adjusted EBITDA for the first quarter was $72 million, down 40% year-over-year, primarily driven by declining prices and unfavorable cost impacts, highlighting the company's struggles in a competitive market environment.
- Strategic Options Evaluation: FMC is actively evaluating multiple strategic alternatives to improve its financial health, aiming to strengthen its balance sheet through targeted debt reduction of approximately $1 billion while driving growth in new active ingredient sales to address future market challenges.
See More
FMC Corporation Reports Q1 2026 Financial Results with Significant Losses
- Revenue Decline: FMC reported Q1 2026 revenue of $759 million, down 4% year-over-year, with revenue excluding India at $762 million, indicating ongoing challenges in global markets, particularly due to a 5% sales headwind from the divestiture of the Indian business.
- Widening Net Loss: The company recorded a GAAP net loss of $281 million in Q1, an increase of $266 million compared to Q1 2025, primarily driven by lower sales, higher restructuring costs, and increased interest expenses, reflecting difficulties in cost control and market competition.
- Significant EBITDA Drop: Adjusted EBITDA for Q1 was $72 million, a 40% decline year-over-year, indicating a substantial weakening in profitability under pressure from pricing and unfavorable costs, necessitating more effective cost management strategies to restore profitability.
- 2026 Outlook Maintained: FMC reaffirmed its 2026 revenue guidance of $3.60 billion to $3.80 billion, expecting a 5% decline year-over-year, while adjusted EBITDA is projected at $670 million to $730 million, demonstrating a cautious approach amid market challenges, although new active ingredient sales are expected to grow over 75%.
See More
FMC Corporation Q1 2026 Earnings Call Insights
- Sales Performance Overview: FMC reported Q1 sales of $762 million, a 4% decline year-over-year, yet a 1% increase on a like-for-like basis after excluding India, demonstrating resilience amid challenging market conditions.
- Debt Management Plan: The company aims to reduce approximately $1 billion in debt during 2026 and expects to sign a definitive agreement for the sale of its India commercial business in May, which will help improve financial health and reduce leverage.
- Product Strategy Shift: FMC is transitioning production from high-cost plants to lower-cost sources in Asia, with completion expected by Q1 2027, thereby enhancing overall production efficiency and reducing costs.
- Future Outlook: The company anticipates Q2 revenue between $850 million and $900 million, with adjusted earnings per share expected to range from $0.16 to $0.26, maintaining full-year guidance despite uncertainties related to Iran and tariffs.
See More
FMC STOCK RISES 11.4% FOLLOWING STRONG Q1 REVENUE AND SMALLER-THAN-EXPECTED LOSS
Revenue Performance: The company reported a revenue increase of 1.4% after exceeding expectations in Q1.
Losses: Despite the revenue beat, the losses were narrower than anticipated.
See More
FMC (FMC) Q1 2026 Earnings Call Transcript
See More
FMC Reports Q1 2026 Earnings with Mixed Results
- Earnings Beat: FMC's Q1 non-GAAP EPS of $0.23 exceeded expectations by $0.61, indicating resilience in profitability despite a 4.1% year-over-year revenue decline.
- Revenue and Loss: The company reported revenue of $759 million, beating estimates by $16.59 million, yet faced a GAAP net loss of $281 million, a decline of $266 million compared to Q1 2025, highlighting ongoing challenges.
- Adjusted EBITDA Decline: Adjusted EBITDA fell to $72 million, down 40% year-over-year, suggesting a need for improved cost control and operational efficiency to navigate market pressures.
- 2026 Outlook Maintained: FMC maintains its full-year 2026 outlook with projected revenue between $3.60 billion and $3.80 billion, reflecting a cautious stance as it anticipates a 5% decline at the midpoint compared to 2025.
See More
FMC Corporation Reports Q1 2026 Financial Results and Strategic Outlook
- Revenue Decline: FMC Corporation reported Q1 2026 revenue of $759 million, a 4% decrease year-over-year, with revenue excluding India at $762 million, indicating significant challenges in the global market, particularly due to a 5% sales headwind from the divestiture of its India business.
- Widening Loss Per Share: The company reported a diluted loss per share of $2.25 for Q1, an increase of $2.13 compared to the same period in 2025, reflecting pressures from restructuring costs and higher interest expenses that have worsened its overall financial condition.
- Significant EBITDA Drop: Adjusted EBITDA for the first quarter was $72 million, down 40% year-over-year, primarily driven by declining prices and unfavorable cost impacts, highlighting the company's struggles in a competitive market environment.
- Strategic Options Evaluation: FMC is actively evaluating multiple strategic alternatives to improve its financial health, aiming to strengthen its balance sheet through targeted debt reduction of approximately $1 billion while driving growth in new active ingredient sales to address future market challenges.
See More
FMC Corporation Reports Q1 2026 Financial Results with Significant Losses
- Revenue Decline: FMC reported Q1 2026 revenue of $759 million, down 4% year-over-year, with revenue excluding India at $762 million, indicating ongoing challenges in global markets, particularly due to a 5% sales headwind from the divestiture of the Indian business.
- Widening Net Loss: The company recorded a GAAP net loss of $281 million in Q1, an increase of $266 million compared to Q1 2025, primarily driven by lower sales, higher restructuring costs, and increased interest expenses, reflecting difficulties in cost control and market competition.
- Significant EBITDA Drop: Adjusted EBITDA for Q1 was $72 million, a 40% decline year-over-year, indicating a substantial weakening in profitability under pressure from pricing and unfavorable costs, necessitating more effective cost management strategies to restore profitability.
- 2026 Outlook Maintained: FMC reaffirmed its 2026 revenue guidance of $3.60 billion to $3.80 billion, expecting a 5% decline year-over-year, while adjusted EBITDA is projected at $670 million to $730 million, demonstrating a cautious approach amid market challenges, although new active ingredient sales are expected to grow over 75%.
See More
